Clinical trial
An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease Based on Humanized Monoclonal Antibodies
NCT04717830 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease Based on Humanized Monoclonal Antibodies
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- February 15, 2021
- Completion date
- January 31, 2022
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ebola virus disease